A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B) - Contacts and Locations

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)

This study has been completed.

Study NCT00000767. Last updated on June 23, 2005. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000767

Locations


United States, Maryland
	Johns Hopkins Univ / School of Hygiene & Public Health
	Baltimore, Maryland, United States, 212051901

United States, Missouri
	St Louis Univ School of Medicine
	St. Louis, Missouri, United States, 63104

United States, New York
	Univ of Rochester Med Ctr
	Rochester, New York, United States, 14642

United States, Tennessee
	Vanderbilt Univ Hosp
	Nashville, Tennessee, United States, 37232

United States, Washington
	Univ of Washington / Pacific Med Ctr
	Seattle, Washington, United States, 98144

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Study Chair:	Keefer M